biosimilars

Predictions for biosimilars: How market access will play outEarly planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
What the new biosimilar means for U.S. healthcarePhysicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.
Biosimilar naming method questionedFDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring.
New biosimilar for RA to save millionsFDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Four things executives need to know to combat rising drug spendExecutives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.
Study: Biosimilars as safe as branded drugsNew study finds that biosimilar medications for arthritis and other diseases areas safe and effective as their brand-name counterparts.
Why pharmacists are concerned about the safety of biosimilarsPharmacists and other healthcare professionals are looking to the FDA for more guidance on biosimilars and interchangeability with their reference products.
Biosimilars for cancer treatment on the U.S. horizonCancer treatments are expected to dominate much of the first wave of biosimilars in the U.S. This Q&A discussion looks at some of the questions pharmacists have about use of biosimilars in cancer treatment.
Biosimilar: Coming to a pharmacy near youBiosimilars are the future of pharmacy. When they hit community pharmacy, issues that have been important in specialty settings are going to explode.